European Commission Approves Legend Biotech's CARVYKTI for 2nd-Line MM
Ticker: LEGN · Form: 6-K · Filed: Apr 22, 2024 · CIK: 1801198
| Field | Detail |
|---|---|
| Company | Legend Biotech Corp (LEGN) |
| Form Type | 6-K |
| Filed Date | Apr 22, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | bullish |
Sentiment: bullish
Topics: regulatory-approval, pharmaceutical, multiple-myeloma, europe
TL;DR
EC approves Legend Biotech's CARVYKTI for earlier multiple myeloma treatment.
AI Summary
On April 22, 2024, Legend Biotech Corporation announced that the European Commission (EC) has approved CARVYKTI® (ciltacabtagene autoleucel, cilta-cel) for the second-line treatment of adult patients with relapsed and refractory multiple myeloma. This approval applies to patients who have received at least one prior therapy, including a proteasome inhibitor and an immunomodulatory agent.
Why It Matters
This European approval expands access to a potentially life-saving treatment for multiple myeloma patients, offering a new option earlier in their treatment journey.
Risk Assessment
Risk Level: low — The filing is a routine announcement of regulatory approval, which is generally positive news and does not introduce new risks.
Key Players & Entities
- Legend Biotech Corporation (company) — Registrant and issuer of the announcement
- CARVYKTI® (product) — Drug approved by the European Commission
- ciltacabtagene autoleucel (product) — Active ingredient of CARVYKTI®
- cilta-cel (product) — Abbreviation for ciltacabtagene autoleucel
- European Commission (company) — Regulatory body granting the approval
- April 22, 2024 (date) — Date of the announcement and approval
FAQ
What specific prior therapies are required for CARVYKTI® approval in the second-line setting?
Patients must have received at least one prior therapy including a proteasome inhibitor (PI) and an immunomodulatory agent (IMiD).
What is the indication for CARVYKTI® in Europe based on this announcement?
CARVYKTI® is approved for the second-line treatment of adult patients with relapsed and refractory multiple myeloma.
Who is the manufacturer of CARVYKTI®?
Legend Biotech Corporation is the company announcing the approval.
When was this approval announced?
The announcement was made on April 22, 2024.
What is the chemical name of the active ingredient in CARVYKTI®?
The active ingredient is ciltacabtagene autoleucel, also referred to as cilta-cel.
Filing Stats: 295 words · 1 min read · ~1 pages · Grade level 14.7 · Accepted 2024-04-22 13:06:33
Filing Documents
- f6k_042224.htm (6-K) — 9KB
- exh_991.htm (EX-99.1) — 48KB
- logo.jpg (GRAPHIC) — 6KB
- 0001171843-24-002118.txt ( ) — 66KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. LEGEND BIOTECH CORPORATION Date: April 22, 2024 By: /s/ Ying Huang Name: Ying Huang, Ph.D. Title: Chief Executive Officer